The evolution of non-small cell lung cancer metastases in TRACERx (2024)

The evolution of non-small cell lung cancer metastases in TRACERx (1) https://doi.org/10.1038/s41586-023-05729-x · The evolution of non-small cell lung cancer metastases in TRACERx (2)

Видання: Nature, 2023, №7957, с.534-542

Видавець: Springer Science and Business Media LLC

Автори:

  1. Maise Al Bakir
  2. Ariana Huebner
  3. Carlos Martínez-Ruiz
  4. Kristiana Grigoriadis
  5. Thomas B. K. Watkins
  6. Oriol Pich
  7. David A. Moore
  8. Selvaraju Veeriah
  9. Sophia Ward
  10. Joanne Layco*ck
  11. Diana Johnson
  12. Andrew Rowan
  13. Maryam Razaq
  14. Mita Akther
  15. Cristina Naceur-Lombardelli
  16. Paulina Prymas
  17. Antonia Toncheva
  18. Sonya Hessey
  19. Michelle Dietzen
  20. Emma Colliver
  21. Alexander M. Frankell
  22. Abigail Bunkum
  23. Emilia L. Lim
  24. Takahiro Karasaki
  25. Christopher Abbosh
  26. Crispin T. Hiley
  27. Mark S. Hill
  28. Daniel E. Cook
  29. Gareth A. Wilson
  30. Roberto Salgado
  31. Emma Nye
  32. Richard Kevin Stone
  33. Dean A. Fennell
  34. Gillian Price
  35. Keith M. Kerr
  36. Babu Naidu
  37. Gary Middleton
  38. Yvonne Summers
  39. Colin R. Lindsay
  40. Fiona H. Blackhall
  41. Judith Cave
  42. Kevin G. Blyth
  43. Arjun Nair
  44. Asia Ahmed
  45. Magali N. Taylor
  46. Alexander James Procter
  47. Mary Falzon
  48. David Lawrence
  49. Neal Navani
  50. Ricky M. Thakrar
  51. Sam M. Janes
  52. Dionysis Papadatos-Pastos
  53. Martin D. Forster
  54. Siow Ming Lee
  55. Tanya Ahmad
  56. Sergio A. Quezada
  57. Karl S. Peggs
  58. Peter Van Loo
  59. Caroline Dive
  60. Allan Hackshaw
  61. Nicolai J. Birkbak
  62. Simone Zaccaria
  63. Jason F. Lester
  64. Amrita Bajaj
  65. Apostolos Nakas
  66. Azmina Sodha-Ramdeen
  67. Keng Ang
  68. Mohamad Tufail
  69. Mohammed Fiyaz Chowdhry
  70. Molly Scotland
  71. Rebecca Boyles
  72. Sridhar Rathinam
  73. Claire Wilson
  74. Domenic Marrone
  75. Sean Dulloo
  76. Gurdeep Matharu
  77. Jacqui A. Shaw
  78. Joan Riley
  79. Lindsay Primrose
  80. Ekaterini Boleti
  81. Heather Cheyne
  82. Mohammed Khalil
  83. Shirley Richardson
  84. Tracey Cruickshank
  85. Sarah Benafif
  86. Kayleigh Gilbert
  87. Akshay J. Patel
  88. Aya Osman
  89. Christer Lacson
  90. Gerald Langman
  91. Helen Shackleford
  92. Madava Djearaman
  93. Salma Kadiri
  94. Angela Leek
  95. Jack Davies Hodgkinson
  96. Nicola Totten
  97. Angeles Montero
  98. Elaine Smith
  99. Eustace Fontaine
  100. Felice Granato
  101. Helen Doran
  102. Juliette Novasio
  103. Kendadai Rammohan
  104. Leena Joseph
  105. Paul Bishop
  106. Rajesh Shah
  107. Stuart Moss
  108. Vijay Joshi
  109. Philip Crosbie
  110. Fabio Gomes
  111. Kate Brown
  112. Mathew Carter
  113. Anshuman Chaturvedi
  114. Lynsey Priest
  115. Pedro Oliveira
  116. Matthew G. Krebs
  117. Alexandra Clipson
  118. Jonathan Tugwood
  119. Alastair Kerr
  120. Dominic G. Rothwell
  121. Elaine Kilgour
  122. Hugo J. W. L. Aerts
  123. Roland F. Schwarz
  124. Tom L. Kaufmann
  125. Rachel Rosenthal
  126. Zoltan Szallasi
  127. Judit Kisistok
  128. Mateo Sokac
  129. Miklos Diossy
  130. Jonas Demeulemeester
  131. Aengus Stewart
  132. Alastair Magness
  133. Angeliki Karamani
  134. Benny Chain
  135. Brittany B. Campbell
  136. Carla Castignani
  137. Chris Bailey
  138. Clare Puttick
  139. Clare E. Weeden
  140. Claudia Lee
  141. Corentin Richard
  142. David R. Pearce
  143. Despoina Karagianni
  144. Dhruva Biswas
  145. Dina Levi
  146. Elena Hoxha
  147. Elizabeth Larose Cadieux
  148. Eva Grönroos
  149. Felip Gálvez-Cancino
  150. Foteini Athanasopoulou
  151. Francisco Gimeno-Valiente
  152. George Kassiotis
  153. Georgia Stavrou
  154. Gerasimos Mastrokalos
  155. Haoran Zhai
  156. Helen L. Lowe
  157. Ignacio Matos
  158. Jacki Goldman
  159. James L. Reading
  160. James R. M. Black
  161. Javier Herrero
  162. Jayant K. Rane
  163. Jerome Nicod
  164. Jie Min Lam
  165. John A. Hartley
  166. Katey S. S. Enfield
  167. Kayalvizhi Selvaraju
  168. Kerstin Thol
  169. Kevin Litchfield
  170. Kevin W. Ng
  171. Kezhong Chen
  172. Krijn Dijkstra
  173. Krupa Thakkar
  174. Leah Ensell
  175. Mansi Shah
  176. Marcos Vasquez
  177. Maria Litovchenko
  178. Mariana Werner Sunderland
  179. Michelle Leung
  180. Mickael Escudero
  181. Mihaela Angelova
  182. Miljana Tanić
  183. Monica Sivakumar
  184. Nnennaya Kanu
  185. Olga Chervova
  186. Olivia Lucas
  187. Othman Al-Sawaf
  188. Philip Hobson
  189. Piotr Pawlik
  190. Robert Bentham
  191. Robert E. Hynds
  192. Roberto Vendramin
  193. Sadegh Saghafinia
  194. Saioa López
  195. Samuel Gamble
  196. Seng Kuong Anakin Ung
  197. Sharon Vanloo
  198. Stefan Boeing
  199. Stephan Beck
  200. Supreet Kaur Bola
  201. Tamara Denner
  202. Teresa Marafioti
  203. Thanos P. Mourikis
  204. Victoria Spanswick
  205. Vittorio Barbè
  206. Wei-Ting Lu
  207. William Hill
  208. Wing Kin Liu
  209. Yin Wu
  210. Yutaka Naito
  211. Zoe Ramsden
  212. Catarina Veiga
  213. Gary Royle
  214. Charles-Antoine Collins-Fekete
  215. Francesco Fraioli
  216. Paul Ashford
  217. Tristan Clark
  218. Elaine Borg
  219. James Wilson
  220. Davide Patrini
  221. Emilie Martinoni Hoogenboom
  222. Fleur Monk
  223. James W. Holding
  224. Junaid Choudhary
  225. Kunal Bhakhri
  226. Marco Scarci
  227. Martin Hayward
  228. Nikolaos Panagiotopoulos
  229. Pat Gorman
  230. Reena Khiroya
  231. Robert C. M. Stephens
  232. Yien Ning Sophia Wong
  233. Steve Bandula
  234. Abigail Sharp
  235. Sean Smith
  236. Nicole Gower
  237. Harjot Kaur Dhanda
  238. Kitty Chan
  239. Camilla Pilotti
  240. Rachel Leslie
  241. Anca Grapa
  242. Hanyun Zhang
  243. Khalid AbdulJabbar
  244. Xiaoxi Pan
  245. Yinyin Yuan
  246. David Chuter
  247. Mairead MacKenzie
  248. Serena Chee
  249. Aiman Alzetani
  250. Lydia Scarlett
  251. Jennifer Richards
  252. Papawadee Ingram
  253. Silvia Austin
  254. Eric Lim
  255. Paulo De Sousa
  256. Simon Jordan
  257. Alexandra Rice
  258. Hilgardt Raubenheimer
  259. Harshil Bhayani
  260. Lyn Ambrose
  261. Anand Devaraj
  262. Hema Chavan
  263. Sofina Begum
  264. Silviu I. Buderi
  265. Daniel Kaniu
  266. Mpho Malima
  267. Sarah Booth
  268. Andrew G. Nicholson
  269. Nadia Fernandes
  270. Pratibha Shah
  271. Chiara Proli
  272. Madeleine Hewish
  273. Sarah Danson
  274. Michael J. Shackcloth
  275. Lily Robinson
  276. Peter Russell
  277. Craig Dick
  278. John Le Quesne
  279. Alan Kirk
  280. Mo Asif
  281. Rocco Bilancia
  282. Nikos Kostoulas
  283. Mathew Thomas
  284. Mariam Jamal-Hanjani
  285. Nicholas McGranahan
  286. Charles Swanton
  287. TRACERx Consortium

Анотація

AbstractMetastatic disease is responsible for the majority of cancer-related deaths1. We report the longitudinal evolutionary analysis of 126 non-small cell lung cancer (NSCLC) tumours from 421 prospectively recruited patients in TRACERx who developed metastatic disease, compared with a control cohort of 144 non-metastatic tumours. In 25% of cases, metastases diverged early, before the last clonal sweep in the primary tumour, and early divergence was enriched for patients who were smokers at the time of initial diagnosis. Simulations suggested that early metastatic divergence more frequently occurred at smaller tumour diameters (less than 8 mm). Single-region primary tumour sampling resulted in 83% of late divergence cases being misclassified as early, highlighting the importance of extensive primary tumour sampling. Polyclonal dissemination, which was associated with extrathoracic disease recurrence, was found in 32% of cases. Primary lymph node disease contributed to metastatic relapse in less than 20% of cases, representing a hallmark of metastatic potential rather than a route to subsequent recurrences/disease progression. Metastasis-seeding subclones exhibited subclonal expansions within primary tumours, probably reflecting positive selection. Our findings highlight the importance of selection in metastatic clone evolution within untreated primary tumours, the distinction between monoclonal versus polyclonal seeding in dictating site of recurrence, the limitations of current radiological screening approaches for early diverging tumours and the need to develop strategies to target metastasis-seeding subclones before relapse.

Список літератури

  1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
    The evolution of non-small cell lung cancer metastases in TRACERx (3) https://doi.org/10.3322/caac.21492
  2. Zappa, C. & Mousa, S. A. Non-small cell lung cancer: current treatment and future advances. Transl. Lung Cancer Res. 5, 288–300 (2016).
    The evolution of non-small cell lung cancer metastases in TRACERx (4) https://doi.org/10.21037/tlcr.2016.06.07
  3. Jamal-Hanjani, M. et al. Tracking the evolution of non–small-cell lung cancer. N. Engl. J. Med. 376, 2109–2121 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (5) https://doi.org/10.1056/NEJMoa1616288
  4. Grigoriadis, K. et al. CONIPHER: a computational framework for scalable phylogenetic reconstruction with error correction. Protoc. Exchange https://doi.org/10.21203/rs.3.pex-2158/v1 (2023).
    The evolution of non-small cell lung cancer metastases in TRACERx (6) https://doi.org/10.21203/rs.3.pex-2158/v1
  5. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251–256 (2014).
    The evolution of non-small cell lung cancer metastases in TRACERx (7) https://doi.org/10.1126/science.1253462
  6. Pich, O. et al. The mutational footprints of cancer therapies. Nat. Genet. 51, 1732–1740 (2019).
    The evolution of non-small cell lung cancer metastases in TRACERx (8) https://doi.org/10.1038/s41588-019-0525-5
  7. Landau, H. J. et al. Accelerated single cell seeding in relapsed multiple myeloma. Nat. Commun. 11, 3617 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (9) https://doi.org/10.1038/s41467-020-17459-z
  8. Pich, O. et al. The evolution of hematopoietic cells under cancer therapy. Nat. Commun. 12, 4803 (2021).
    The evolution of non-small cell lung cancer metastases in TRACERx (10) https://doi.org/10.1038/s41467-021-24858-3
  9. Sun, R. et al. Between-region genetic divergence reflects the mode and tempo of tumor evolution. Nat. Genet. 49, 1015–1024 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (11) https://doi.org/10.1038/ng.3891
  10. Bueno, J., Landeras, L. & Chung, J. H. Updated Fleischner society guidelines for managing incidental pulmonary nodules: common questions and challenging scenarios. Radiographics 38, 1337–1350 (2018).
    The evolution of non-small cell lung cancer metastases in TRACERx (12) https://doi.org/10.1148/rg.2018180017
  11. Callister, M. E. J. et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax 70, ii1–ii54 (2015).
    The evolution of non-small cell lung cancer metastases in TRACERx (13) https://doi.org/10.1136/thoraxjnl-2015-207168
  12. Horeweg, N. et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. Lancet Oncol. 15, 1332–1341 (2014).
    The evolution of non-small cell lung cancer metastases in TRACERx (14) https://doi.org/10.1016/S1470-2045(14)70389-4
  13. de Koning, H. J. et al. Reduced lung-cancer mortality with volume CT screening in a randomized trial. N. Engl. J. Med. 382, 503–513 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (15) https://doi.org/10.1056/NEJMoa1911793
  14. Oudkerk, M. et al. European position statement on lung cancer screening. Lancet Oncol. 18, e754–e766 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (16) https://doi.org/10.1016/S1470-2045(17)30861-6
  15. MacMahon, H. et al. Guidelines for management of incidental pulmonary nodules detected on CT images: from the Fleischner Society 2017. Radiology 284, 228–243 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (17) https://doi.org/10.1148/radiol.2017161659
  16. American College of Radiology Committee on Lung-RADS. Lung-RADS Assessment Categories version 1.1 (ACR, 2019); https://www.acr.org/-/media/ACR/Files/RADS/Lung-RADS/LungRADSAssessmentCategoriesv1-1.pdf.
  17. Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature https://doi.org/10.1038/s41586-023-05783-5 (2023).
    The evolution of non-small cell lung cancer metastases in TRACERx (18) https://doi.org/10.1038/s41586-023-05783-5
  18. El-Kebir, M., Satas, G. & Raphael, B. J. Inferring parsimonious migration histories for metastatic cancers. Nat. Genet. 50, 718–726 (2018).
    The evolution of non-small cell lung cancer metastases in TRACERx (19) https://doi.org/10.1038/s41588-018-0106-z
  19. Abbosh, C. et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature https://doi.org/10.1038/s41586-023-05776-4 (2023).
    The evolution of non-small cell lung cancer metastases in TRACERx (20) https://doi.org/10.1038/s41586-023-05776-4
  20. Martincorena, I. et al. Universal patterns of selection in cancer and somatic tissues. Cell 171, 1029–1041 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (21) https://doi.org/10.1016/j.cell.2017.09.042
  21. Bailey, M. H. et al. Comprehensive characterization of cancer driver genes and mutations. Cell 174, 1034–1035 (2018).
    The evolution of non-small cell lung cancer metastases in TRACERx (22) https://doi.org/10.1016/j.cell.2018.07.034
  22. Mermel, C. H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
    The evolution of non-small cell lung cancer metastases in TRACERx (23) https://doi.org/10.1186/gb-2011-12-4-r41
  23. Lee, W.-C. et al. Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity. Genome Biol. 21, 271 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (24) https://doi.org/10.1186/s13059-020-02175-0
  24. Brown, D. et al. Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations. Nat. Commun. 8, 14944 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (25) https://doi.org/10.1038/ncomms14944
  25. Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490–1499 (2016).
    The evolution of non-small cell lung cancer metastases in TRACERx (26) https://doi.org/10.1038/ng.3692
  26. Hu, Z. et al. Quantitative evidence for early metastatic seeding in colorectal cancer. Nat. Genet. 51, 1113–1122 (2019).
    The evolution of non-small cell lung cancer metastases in TRACERx (27) https://doi.org/10.1038/s41588-019-0423-x
  27. Naxerova, K. et al. Origins of lymphatic and distant metastases in human colorectal cancer. Science 357, 55–60 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (28) https://doi.org/10.1126/science.aai8515
  28. Kim, T.-M. et al. Subclonal genomic architectures of primary and metastatic colorectal cancer based on intratumoral genetic heterogeneity. Clin. Cancer Res. 21, 4461–4472 (2015).
    The evolution of non-small cell lung cancer metastases in TRACERx (29) https://doi.org/10.1158/1078-0432.CCR-14-2413
  29. Zhao, Z.-M. et al. Early and multiple origins of metastatic lineages within primary tumors. Proc. Natl Acad. Sci. USA 113, 2140–2145 (2016).
    The evolution of non-small cell lung cancer metastases in TRACERx (30) https://doi.org/10.1073/pnas.1525677113
  30. Zhai, W. et al. The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma. Nat. Commun. 8, 4565 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (31) https://doi.org/10.1038/ncomms14565
  31. Gibson, W. J. et al. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nat. Genet. 48, 848–855 (2016).
    The evolution of non-small cell lung cancer metastases in TRACERx (32) https://doi.org/10.1038/ng.3602
  32. Reiter, J. G. et al. Lymph node metastases develop through a wider evolutionary bottleneck than distant metastases. Nat. Genet. 52, 692–700 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (33) https://doi.org/10.1038/s41588-020-0633-2
  33. Tang, W.-F. et al. Timing and origins of local and distant metastases in lung cancer. J. Thorac. Oncol. 16, 1136–1148 (2021).
    The evolution of non-small cell lung cancer metastases in TRACERx (34) https://doi.org/10.1016/j.jtho.2021.02.023
  34. Tan, Q. et al. Genomic alteration during metastasis of lung adenocarcinoma. Cell. Physiol. Biochem. 38, 469–486 (2016).
    The evolution of non-small cell lung cancer metastases in TRACERx (35) https://doi.org/10.1159/000438644
  35. Hu, Z., Li, Z., Ma, Z. & Curtis, C. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases. Nat. Genet. 52, 701–708 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (36) https://doi.org/10.1038/s41588-020-0628-z
  36. Ullah, I. et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. J. Clin. Invest. 128, 1355–1370 (2018).
    The evolution of non-small cell lung cancer metastases in TRACERx (37) https://doi.org/10.1172/JCI96149
  37. Haffner, M. C. et al. Tracking the clonal origin of lethal prostate cancer. J. Clin. Invest. 123, 4918–4922 (2013).
    The evolution of non-small cell lung cancer metastases in TRACERx (38) https://doi.org/10.1172/JCI70354
  38. Noorani, A. et al. Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma. Nat. Genet. 52, 74–83 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (39) https://doi.org/10.1038/s41588-019-0551-3
  39. Gundem, G. et al. The evolutionary history of lethal metastatic prostate cancer. Nature 520, 353–357 (2015).
    The evolution of non-small cell lung cancer metastases in TRACERx (40) https://doi.org/10.1038/nature14347
  40. Chen, H.-N. et al. Genomic evolution and diverse models of systemic metastases in colorectal cancer. Gut 71, 322–332 (2022).
    The evolution of non-small cell lung cancer metastases in TRACERx (41) https://doi.org/10.1136/gutjnl-2020-323703
  41. Abbosh, C. et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature 545, 446–451 (2017).
    The evolution of non-small cell lung cancer metastases in TRACERx (42) https://doi.org/10.1038/nature22364
  42. Turajlic, S. et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 173, 581–594 (2018).
    The evolution of non-small cell lung cancer metastases in TRACERx (43) https://doi.org/10.1016/j.cell.2018.03.057
  43. Bailey, C. et al. Tracking cancer evolution through the disease course. Cancer Discov. 11, 916–932 (2021).
    The evolution of non-small cell lung cancer metastases in TRACERx (44) https://doi.org/10.1158/2159-8290.CD-20-1559
  44. Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).
    The evolution of non-small cell lung cancer metastases in TRACERx (45) https://doi.org/10.1186/s13059-016-0893-4
  45. Alexandrov, L. B. et al. The repertoire of mutational signatures in human cancer. Nature 578, 94–101 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (46) https://doi.org/10.1038/s41586-020-1943-3
  46. Boot, A. et al. In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors. Genome Res. 28, 654–665 (2018).
    The evolution of non-small cell lung cancer metastases in TRACERx (47) https://doi.org/10.1101/gr.230219.117
  47. Sottoriva, A. et al. A Big Bang model of human colorectal tumor growth. Nat. Genet. 47, 209–216 (2015).
    The evolution of non-small cell lung cancer metastases in TRACERx (48) https://doi.org/10.1038/ng.3214
  48. Cannataro, V. L., McKinley, S. A. & St Mary, C. M. The implications of small stem cell niche sizes and the distribution of fitness effects of new mutations in aging and tumorigenesis. Evol. Appl. 9, 565–582 (2016).
    The evolution of non-small cell lung cancer metastases in TRACERx (49) https://doi.org/10.1111/eva.12361
  49. Lebeuf-Taylor, E., McCloskey, N., Bailey, S. F., Hinz, A. & Kassen, R. The distribution of fitness effects among synonymous mutations in a gene under directional selection. eLife 8, e45952 (2019).
    The evolution of non-small cell lung cancer metastases in TRACERx (50) https://doi.org/10.7554/eLife.45952
  50. Eyre-Walker, A. & Keightley, P. D. The distribution of fitness effects of new mutations. Nat. Rev. Genet. 8, 610–618 (2007).
    The evolution of non-small cell lung cancer metastases in TRACERx (51) https://doi.org/10.1038/nrg2146
  51. Bozic, I. et al. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl Acad. Sci. USA 107, 18545–18550 (2010).
    The evolution of non-small cell lung cancer metastases in TRACERx (52) https://doi.org/10.1073/pnas.1010978107
  52. Williams, M. J. et al. Measuring the distribution of fitness effects in somatic evolution by combining clonal dynamics with dN/dS ratios. eLife 9, e48714 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (53) https://doi.org/10.7554/eLife.48714
  53. Turajlic, S., Sottoriva, A., Graham, T. & Swanton, C. Resolving genetic heterogeneity in cancer. Nat. Rev. Genet. 20, 404–416 (2019).
    The evolution of non-small cell lung cancer metastases in TRACERx (54) https://doi.org/10.1038/s41576-019-0114-6
  54. Venkatesan, S. et al. Induction of APOBEC3 exacerbates DNA replication stress and chromosomal instability in early breast and lung cancer evolution. Cancer Discov. 11, 2456–2473 (2021).
    The evolution of non-small cell lung cancer metastases in TRACERx (55) https://doi.org/10.1158/2159-8290.CD-20-0725
  55. Dewhurst, S. M. et al. Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4, 175–185 (2014).
    The evolution of non-small cell lung cancer metastases in TRACERx (56) https://doi.org/10.1158/2159-8290.CD-13-0285
  56. Werner, B. et al. Measuring single cell divisions in human tissues from multi-region sequencing data. Nat. Commun. 11, 1035 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (57) https://doi.org/10.1038/s41467-020-14844-6
  57. Del Monte, U. Does the cell number 109 still really fit one gram of tumor tissue? Cell Cycle 8, 505–506 (2009).
    The evolution of non-small cell lung cancer metastases in TRACERx (58) https://doi.org/10.4161/cc.8.3.7608
  58. McGranahan, N. et al. Clonal status of actionable driver events and the timing of mutational processes in cancer evolution. Sci. Transl. Med. 7, 283ra54 (2015).
    The evolution of non-small cell lung cancer metastases in TRACERx (59) https://doi.org/10.1126/scitranslmed.aaa1408
  59. Berger, A. H. et al. High-throughput phenotyping of lung cancer somatic mutations. Cancer Cell 30, 214 (2016).
    The evolution of non-small cell lung cancer metastases in TRACERx (60) https://doi.org/10.1016/j.ccell.2016.06.022
  60. Lawson, A. R. J. et al. Extensive heterogeneity in somatic mutation and selection in the human bladder. Science 370, 75–82 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (61) https://doi.org/10.1126/science.aba8347
  61. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289–300 (1995).
  62. Watkins, T. B. K. et al. Pervasive chromosomal instability and karyotype order in tumour evolution. Nature 587, 126–132 (2020).
    The evolution of non-small cell lung cancer metastases in TRACERx (62) https://doi.org/10.1038/s41586-020-2698-6
  63. Frankell A. M., Colliver E., Mcgranahan N., Swanton C. cloneMap: a R package to visualise clonal heterogeneity. Preprint at bioRxiv https://doi.org/10.1101/2022.07.26.501523 (2022).
    The evolution of non-small cell lung cancer metastases in TRACERx (63) https://doi.org/10.1101/2022.07.26.501523

Публікації, які цитують цю публікацію

Mechanisms of lymph node metastasis: An extracellular vesicle perspective

Susana García-Silva, Héctor Peinado

The evolution of non-small cell lung cancer metastases in TRACERx (64) https://doi.org/10.1016/j.ejcb.2024.151447 · The evolution of non-small cell lung cancer metastases in TRACERx (65)

2024, European Journal of Cell Biology, №3, с.151447

Scopus

WoS

Цитувань Crossref:0

Sub-lobar resections for peripheral non-small cell lung cancer measuring ≤ 2 cm: Insights from recent clinical trials

Suresh Senan, Famke L. Schneiders, Drew Moghanaki

The evolution of non-small cell lung cancer metastases in TRACERx (66) https://doi.org/10.1016/j.radonc.2024.110094 · The evolution of non-small cell lung cancer metastases in TRACERx (67)

How important is EMT for cancer metastasis?

Toni Celià-Terrassa, Yibin Kang

The evolution of non-small cell lung cancer metastases in TRACERx (68) https://doi.org/10.1371/journal.pbio.3002487 · The evolution of non-small cell lung cancer metastases in TRACERx (69)

2024, PLOS Biology, №2, с.e3002487

Scopus

WoS

Цитувань Crossref:0

A Lung Cancer Mouse Model Database

Ling Cai, Ying Gao, Ralph J. DeBerardinis, George Acquaah-Mensah, Vassilis Aidinis, Jennifer E. Beane, Shyam Biswal, Ting Chen, Carla P. Concepcion-Crisol, Barbara M. Grüner, Deshui Jia, Robert Jones, Jonathan M. Kurie, Min Gyu Lee, Per Lindahl, Yonathan Lissanu, Maria Corina Lorz Lopez, Rosanna Martinelli, Pawel K. Mazur, Sarah A. Mazzilli, Shinji Mii, Herwig Moll, Roger Moorehead, Edward E. Morrisey, Sheng Rong Ng, Matthew G. Oser, Arun R. Pandiri, Charles A. Powell, Giorgio Ramadori, Mirentxu Santos Lafuente, Eric Snyder, Rocio Sotillo, Kang-Yi Su, Tetsuro Taki, Kekoa Taparra, Yifeng Xia, Ed van Veen, Monte M. Winslow, Guanghua Xiao, Charles M. Rudin, Trudy G. Oliver, Yang Xie, John D. Minna

The evolution of non-small cell lung cancer metastases in TRACERx (70) https://doi.org/10.1101/2024.02.28.582577

2024

Цитувань Crossref:0

Epigenetic markers and therapeutic targets for metastasis

Carolyn J. Kravitz, Qin Yan, Don X. Nguyen

The evolution of non-small cell lung cancer metastases in TRACERx (71) https://doi.org/10.1007/s10555-023-10109-y

2023, Cancer and Metastasis Reviews, №2, с.427-443

Scopus

WoS

Цитувань Crossref:0

The two sides of chromosomal instability: drivers and brakes in cancer

Rendy Hosea, Sharon Hillary, Sumera Naqvi, Shourong Wu, Vivi Kasim

The evolution of non-small cell lung cancer metastases in TRACERx (72) https://doi.org/10.1038/s41392-024-01767-7 · The evolution of non-small cell lung cancer metastases in TRACERx (73)

2024, Signal Transduction and Targeted Therapy, №1

Scopus

WoS

Цитувань Crossref:0

Exploring evolutionary trajectories in ovarian cancer patients by longitudinal analysis of ctDNA

Oliver Kutz, Stephan Drukewitz, Alexander Krüger, Daniela Aust, Doreen William, Sandra Oster, Evelin Schröck, Gustavo Baretton, Theresa Link, Pauline Wimberger, Jan Dominik Kuhlmann

The evolution of non-small cell lung cancer metastases in TRACERx (74) https://doi.org/10.1515/cclm-2023-1266 · The evolution of non-small cell lung cancer metastases in TRACERx (75)

2024, Clinical Chemistry and Laboratory Medicine (CCLM), №10, с.2070-2081

Scopus

WoS

Цитувань Crossref:0

Insights into the metastatic cascade through research autopsies

Sonya Hessey, Petros Fessas, Simone Zaccaria, Mariam Jamal-Hanjani, Charles Swanton

The evolution of non-small cell lung cancer metastases in TRACERx (76) https://doi.org/10.1016/j.trecan.2023.03.002

2023, Trends in Cancer, №6, с.490-502

Scopus

WoS

Цитувань Crossref:4

Genomic–transcriptomic evolution in lung cancer and metastasis

Carlos Martínez-Ruiz, James R. M. Black, Clare Puttick, Mark S. Hill, Jonas Demeulemeester, Elizabeth Larose Cadieux, Kerstin Thol, Thomas P. Jones, Selvaraju Veeriah, Cristina Naceur-Lombardelli, Antonia Toncheva, Paulina Prymas, Andrew Rowan, Sophia Ward, Laura Cubitt, Foteini Athanasopoulou, Oriol Pich, Takahiro Karasaki, David A. Moore, Roberto Salgado, Emma Colliver, Carla Castignani, Michelle Dietzen, Ariana Huebner, Maise Al Bakir, Miljana Tanić, Thomas B. K. Watkins, Emilia L. Lim, Ali M. Al-Rashed, Danny Lang, James Clements, Daniel E. Cook, Rachel Rosenthal, Gareth A. Wilson, Alexander M. Frankell, Sophie de Carné Trécesson, Philip East, Nnennaya Kanu, Kevin Litchfield, Nicolai J. Birkbak, Allan Hackshaw, Stephan Beck, Peter Van Loo, Mariam Jamal-Hanjani, Nicholas McGranahan, Charles Swanton, Maise Al Bakir, Emilia L. Lim, Alexander M. Frankell, Kevin Litchfield, Nicolai J. Birkbak, Peter Van Loo, Jason F. Lester, Amrita Bajaj, Apostolos Nakas, Azmina Sodha-Ramdeen, Keng Ang, Mohamad Tufail, Mohammed Fiyaz Chowdhry, Molly Scotland, Rebecca Boyles, Sridhar Rathinam, Claire Wilson, Domenic Marrone, Sean Dulloo, Dean A. Fennell, Gurdeep Matharu, Jacqui A. Shaw, Joan Riley, Lindsay Primrose, Ekaterini Boleti, Heather Cheyne, Mohammed Khalil, Shirley Richardson, Tracey Cruickshank, Gillian Price, Keith M. Kerr, Sarah Benafif, Kayleigh Gilbert, Babu Naidu, Akshay J. Patel, Aya Osman, Christer Lacson, Gerald Langman, Helen Shackleford, Madava Djearaman, Salma Kadiri, Gary Middleton, Angela Leek, Jack Davies Hodgkinson, Nicola Totten, Angeles Montero, Elaine Smith, Eustace Fontaine, Felice Granato, Helen Doran, Juliette Novasio, Kendadai Rammohan, Leena Joseph, Paul Bishop, Rajesh Shah, Stuart Moss, Vijay Joshi, Philip Crosbie, Fabio Gomes, Kate Brown, Mathew Carter, Anshuman Chaturvedi, Lynsey Priest, Pedro Oliveira, Colin R. Lindsay, Fiona H. Blackhall, Matthew G. Krebs, Yvonne Summers, Alexandra Clipson, Jonathan Tugwood, Alastair Kerr, Dominic G. Rothwell, Elaine Kilgour, Caroline Dive, Hugo J. W. L. Aerts, Roland F. Schwarz, Tom L. Kaufmann, Zoltan Szallasi, Judit Kisistok, Mateo Sokac, Miklos Diossy, Abigail Bunkum, Aengus Stewart, Alastair Magness, Angeliki Karamani, Benny Chain, Brittany B. Campbell, Chris Bailey, Christopher Abbosh, Clare E. Weeden, Claudia Lee, Corentin Richard, Crispin T. Hiley, David R. Pearce, Despoina Karagianni, Dhruva Biswas, Dina Levi, Elena Hoxha, Emma Nye, Eva Grönroos, Felip Gálvez-Cancino, Francisco Gimeno-Valiente, George Kassiotis, Georgia Stavrou, Gerasimos Mastrokalos, Haoran Zhai, Helen L. Lowe, Ignacio Garcia Matos, Jacki Goldman, James L. Reading, Javier Herrero, Jayant K. Rane, Jerome Nicod, Jie Min Lam, John A. Hartley, Karl S. Peggs, Katey S. S. Enfield, Kayalvizhi Selvaraju, Kevin W. Ng, Kezhong Chen, Krijn Dijkstra, Kristiana Grigoriadis, Krupa Thakkar, Leah Ensell, Mansi Shah, Marcos Vasquez Duran, Maria Litovchenko, Mariana Werner Sunderland, Michelle Leung, Mickael Escudero, Mihaela Angelova, Monica Sivakumar, Olga Chervova, Olivia Lucas, Othman Al-Sawaf, Philip Hobson, Piotr Pawlik, Richard Kevin Stone, Robert Bentham, Robert E. Hynds, Roberto Vendramin, Sadegh Saghafinia, Saioa López, Samuel Gamble, Seng Kuong Anakin Ung, Sergio A. Quezada, Sharon Vanloo, Simone Zaccaria, Sonya Hessey, Stefan Boeing, Supreet Kaur Bola, Tamara Denner, Teresa Marafioti, Thanos P. Mourikis, Victoria Spanswick, Vittorio Barbè, Wei-Ting Lu, William Hill, Wing Kin Liu, Yin Wu, Yutaka Naito, Zoe Ramsden, Catarina Veiga, Gary Royle, Charles-Antoine Collins-Fekete, Francesco Fraioli, Paul Ashford, Tristan Clark, Martin D. Forster, Siow Ming Lee, Elaine Borg, Mary Falzon, Dionysis Papadatos-Pastos, James Wilson, Tanya Ahmad, Alexander James Procter, Asia Ahmed, Magali N. Taylor, Arjun Nair, David Lawrence, Davide Patrini, Neal Navani, Ricky M. Thakrar, Sam M. Janes, Emilie Martinoni Hoogenboom, Fleur Monk, James W. Holding, Junaid Choudhary, Kunal Bhakhri, Marco Scarci, Martin Hayward, Nikolaos Panagiotopoulos, Pat Gorman, Reena Khiroya, Robert C. M. Stephens, Yien Ning Sophia Wong, Steve Bandula, Abigail Sharp, Sean Smith, Nicole Gower, Harjot Kaur Dhanda, Kitty Chan, Camilla Pilotti, Rachel Leslie, Anca Grapa, Hanyun Zhang, Khalid AbdulJabbar, Xiaoxi Pan, Yinyin Yuan, David Chuter, Mairead MacKenzie, Serena Chee, Aiman Alzetani, Judith Cave, Lydia Scarlett, Jennifer Richards, Papawadee Ingram, Silvia Austin, Eric Lim, Paulo De Sousa, Simon Jordan, Alexandra Rice, Hilgardt Raubenheimer, Harshil Bhayani, Lyn Ambrose, Anand Devaraj, Hema Chavan, Sofina Begum, Silviu I. Buderi, Daniel Kaniu, Mpho Malima, Sarah Booth, Andrew G. Nicholson, Nadia Fernandes, Pratibha Shah, Chiara Proli, Madeleine Hewish, Sarah Danson, Michael J. Shackcloth, Lily Robinson, Peter Russell, Kevin G. Blyth, Craig Dick, John Le Quesne, Alan Kirk, Mo Asif, Rocco Bilancia, Nikos Kostoulas, Mathew Thomas, Charles Swanton, Nicholas McGranahan, TRACERx Consortium

The evolution of non-small cell lung cancer metastases in TRACERx (77) https://doi.org/10.1038/s41586-023-05706-4 · The evolution of non-small cell lung cancer metastases in TRACERx (78)

2023, Nature, №7957, с.543-552

Scopus

WoS

Цитувань Crossref:25

Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Kevin W. Ng, Jesse Boumelha, Katey S. S. Enfield, Jorge Almagro, Hongui Cha, Oriol Pich, Takahiro Karasaki, David A. Moore, Roberto Salgado, Monica Sivakumar, George Young, Miriam Molina-Arcas, Sophie de Carné Trécesson, Panayiotis Anastasiou, Annika Fendler, Lewis Au, Scott T. C. Shepherd, Carlos Martínez-Ruiz, Clare Puttick, James R. M. Black, Thomas B. K. Watkins, Hyemin Kim, Seohee Shim, Nikhil Faulkner, Jan Attig, Selvaraju Veeriah, Neil Magno, Sophia Ward, Alexander M. Frankell, Maise Al Bakir, Emilia L. Lim, Mark S. Hill, Gareth A. Wilson, Daniel E. Cook, Nicolai J. Birkbak, Axel Behrens, Nadia Yousaf, Sanjay Popat, Allan Hackshaw, Andrew Rowan, Ariana Huebner, Brittany B. Campbell, Chris Bailey, Claudia Lee, Dhruva Biswas, Emma Colliver, Foteini Athanasopoulou, Haoran Zhai, Jayant K. Rane, Kristiana Grigoriadis, Michelle Dietzen, Michelle Leung, Mihaela Angelova, Olivia Lucas, Othman Al-Sawaf, Rachel Rosenthal, Jerome Nicod, Abigail Bunkum, Antonia Toncheva, Christopher Abbosh, Corentin Richard, Cristina Naceur-Lombardelli, Francisco Gimeno-Valiente, Jie Min Lam, Kerstin Thol, Krupa Thakkar, Mariana Werner Sunderland, Martin D. Forster, Nnennaya Kanu, Paulina Prymas, Robert Bentham, Sadegh Saghafinia, Sergio A. Quezada, Sharon Vanloo, Simone Zaccaria, Siow Ming Lee, Sonya Hessey, Wing Kin Liu, Dionysis Papadatos-Pastos, James Wilson, Sarah Benafif, Tanya Ahmad, Elaine Borg, Mary Falzon, Reena Khiroya, Teresa Marafioti, Abigail Sharp, Camilla Pilotti, Harjot Kaur Dhanda, Kitty Chan, Nicole Gower, Rachel Leslie, Sean Smith, Andrew G. Nicholson, Eric Lim, Javier Herrero, Carla Castignani, Elizabeth Larose Cadieux, Jonas Demeulemeester, Peter Van Loo, Karl S. Peggs, Catarina Veiga, Gary Royle, Charles-Antoine Collins-Fekete, Alexander James Procter, Arjun Nair, Asia Ahmed, Magali N. Taylor, Neal Navani, Ricky M. Thakrar, David Lawrence, Davide Patrini, Emma Nye, Richard Kevin Stone, David Chuter, Mairead MacKenzie, Francesco Fraioli, Paul Ashford, Sam M. Janes, Miljana Tanić, Stephan Beck, Alexandra Rice, Anand Devaraj, Chiara Proli, Daniel Kaniu, Harshil Bhayani, Hema Chavan, Hilgardt Raubenheimer, Lyn Ambrose, Mpho Malima, Nadia Fernandes, Paulo De Sousa, Pratibha Shah, Sarah Booth, Silviu I. Buderi, Simon Jordan, Sofina Begum, Ekaterini Boleti, Aengus Stewart, Alastair Magness, Clare E. Weeden, Dina Levi, Eva Grönroos, Jacki Goldman, Mickael Escudero, Philip Hobson, Roberto Vendramin, Stefan Boeing, Tamara Denner, Vittorio Barbè, Wei-Ting Lu, William Hill, Yutaka Naito, Zoe Ramsden, Anca Grapa, Hanyun Zhang, Khalid AbdulJabbar, Xiaoxi Pan, Kayleigh Gilbert, Angeliki Karamani, Benny Chain, David R. Pearce, Despoina Karagianni, Elena Hoxha, Felip Gálvez-Cancino, Georgia Stavrou, Gerasimos Mastrokalos, Helen L. Lowe, Ignacio Matos, James L. Reading, John A. Hartley, Kayalvizhi Selvaraju, Kezhong Chen, Leah Ensell, Mansi Shah, Marcos Vasquez, Maria Litovchenko, Olga Chervova, Piotr Pawlik, Robert E. Hynds, Saioa López, Samuel Gamble, Seng Kuong Anakin Ung, Supreet Kaur Bola, Thanos P. Mourikis, Victoria Spanswick, Yin Wu, Emilie Martinoni Hoogenboom, Fleur Monk, James W. Holding, Junaid Choudhary, Kunal Bhakhri, Marco Scarci, Martin Hayward, Nikolaos Panagiotopoulos, Pat Gorman, Robert C. M. Stephens, Steve Bandula, Yien Ning Sophia Wong, Tristan Clark, Heather Cheyne, Mohammed Khalil, Shirley Richardson, Tracey Cruickshank, Babu Naidu, Gurdeep Matharu, Jacqui A. Shaw, Joan Riley, Lindsay Primrose, John Le Quesne, Kevin G. Blyth, Alastair Kerr, Alexandra Clipson, Anshuman Chaturvedi, Caroline Dive, Dominic G. Rothwell, Elaine Kilgour, Jonathan Tugwood, Lynsey Priest, Pedro Oliveira, Philip Crosbie, Gillian Price, Judith Cave, Keith M. Kerr, Colin R. Lindsay, Fiona H. Blackhall, Matthew G. Krebs, Yvonne Summers, Alan Kirk, Mathew Thomas, Mo Asif, Nikos Kostoulas, Rocco Bilancia, Gary Middleton, Michael J. Shackcloth, Angela Leek, Jack Davies Hodgkinson, Nicola Totten, Craig Dick, Lily Robinson, Peter Russell, Madeleine Hewish, Sarah Danson, Jason F. Lester, Fabio Gomes, Kate Brown, Mathew Carter, Akshay J. Patel, Aya Osman, Christer Lacson, Gerald Langman, Helen Shackleford, Madava Djearaman, Salma Kadiri, Aiman Alzetani, Jennifer Richards, Lydia Scarlett, Papawadee Ingram, Serena Chee, Silvia Austin, Amrita Bajaj, Apostolos Nakas, Azmina Sodha-Ramdeen, Dean A. Fennell, Keng Ang, Mohamad Tufail, Mohammed Fiyaz Chowdhry, Molly Scotland, Rebecca Boyles, Sridhar Rathinam, Claire Wilson, Domenic Marrone, Sean Dulloo, Angeles Montero, Elaine Smith, Eustace Fontaine, Felice Granato, Helen Doran, Juliette Novasio, Kendadai Rammohan, Leena Joseph, Paul Bishop, Rajesh Shah, Stuart Moss, Vijay Joshi, Hugo J. W. L. Aerts, Tom L. Kaufmann, Roland F. Schwarz, Judit Kisistok, Mateo Sokac, Miklos Diossy, Zoltan Szallasi, Krijn Dijkstra, Yinyin Yuan, Fiona Byrne, Laura Amanda Boos, Benjamin Shum, Camille L. Gerard, Andreas M. Schmitt, Christina Messiou, David Cunningham, Ian Chau, Naureen Starling, Nicholas Turner, Liam Welsh, Robin L. Jones, Joanne Droney, Susana Banerjee, Kate C. Tatham, Shaman Jhanji, Kevin Harrington, Alicia Okines, Alison Reid, Kate Young, Andrew J. S. Furness, Lisa Pickering, Emma Nicholson, Sacheen Kumar, Katalin A. Wilkinson, Anthony Swerdlow, Robert J. Wilkinson, Crispin T. Hiley, Kevin Litchfield, Nicholas McGranahan, Mariam Jamal-Hanjani, James Larkin, Se-Hoon Lee, Samra Turajlic, Charles Swanton, Julian Downward, George Kassiotis, TRACERx Consortium, CAPTURE Consortium

The evolution of non-small cell lung cancer metastases in TRACERx (79) https://doi.org/10.1038/s41586-023-05771-9 · The evolution of non-small cell lung cancer metastases in TRACERx (80)

2023, Nature, №7957, с.563-573

Scopus

WoS

Цитувань Crossref:1

Знайти всі цитування публікації

The evolution of non-small cell lung cancer metastases in TRACERx (2024)

FAQs

How long does it take for non-small cell lung cancer to metastasize? ›

How Quickly Does Non-Small Cell Lung Cancer Spread and Progress? Non-small cell lung cancer (NSCLC) may spread at different rates. Research suggests the average time for a tumor to double in size is around 7 months. However, this is different for everyone.

How long can you live with non-small cell lung cancer? ›

Outlook / Prognosis

This means that 63% of people diagnosed with the condition are still alive five years later. The five-year survival rate for regional NSCLC (when the cancer has spread to nearby tissues or lymph nodes) is 35%. With metastatic non-small cell lung cancer, the five-year survival rate is 7%.

What is the most common metastatic site of non-small cell lung cancer? ›

Distant metastases at the time of presentation of non-small-cell lung cancer (NSCLC) are a frequent clinical problem. Approximately 30–40% of NSCLC patients present with metastatic disease at the time of diagnosis (1, 2). The most common metastatic site is bone, followed by the lungs, brain, liver and adrenal glands.

What is TRACERx study? ›

TRACERx is a major research initiative which takes practical steps to make precision medicine for lung cancer patients a reality. Using cutting-edge methods to collect and analyse genomic data, TRACERx aims to identify patients who could benefit from trials of new targeted treatments.

How long can you live with lung metastasis? ›

Outlook (Prognosis)

A cure is unlikely in most cases of cancers that have spread to the lungs. But the outlook depends on the main cancer. In some cases, a person can live more than 5 years with metastatic cancer to the lungs.

Can non-small cell lung cancer go into remission? ›

— American Society of Clinical Oncology (ASCO)

Up to 80% of NSCLC patients achieved at least partial remission when treated with an immunotherapy drug called Keytruda® (pembrolizumab) before surgery, as noted by a 2020 report from the journal Translational Lung Cancer Research.

What is the first hint of non-small cell lung cancer? ›

Signs of non-small cell lung cancer include a cough that doesn't go away and shortness of breath. Sometimes lung cancer does not cause any signs or symptoms. It may be found during a chest x-ray done for another condition. Signs and symptoms may be caused by lung cancer or by other conditions.

Has anyone beaten non-small cell lung cancer? ›

NSCLC is treatable, especially if treatment starts before the cancer spreads to other body parts. If the cancer is limited to a small part of your lungs, it may be treatable with surgery alone. A more advanced cancer may require additional treatments.

What part of the body hurts when you have lung cancer? ›

The most common symptoms of lung cancer include:

Chest pain that is constant and often made worse by deep breathing, coughing or laughing. Arm or shoulder pain. Coughing up blood or rust-colored phlegm. Shortness of breath.

What is worse non-small cell lung cancer? ›

Small cell lung cancer (SCLC)

This type of lung cancer tends to grow and spread faster than NSCLC. In most people with SCLC, the cancer has already spread beyond the lungs at the time it is diagnosed. Since this cancer grows quickly, it tends to respond well to chemotherapy and radiation therapy.

Who is most likely to get non-small cell lung cancer? ›

“While many non-smokers can get lung cancer, the most prevalent risk factor for NSCLC is smoking,” explains Yale Medicine's Roy S. Herbst, MD, PhD, Yale Cancer Center's chief of medical oncology.

What stage is metastatic non-small cell lung cancer? ›

In stage IV cancer, the tumor has spread (metastasized) somewhere distant from the original tumor. This could include spread to the other side of the chest or to other places in the body such as the bones, the brain, the liver, or the adrenal glands.

Where does lung CA metastasis to? ›

The most common areas for lung cancer to spread to are: nearby lymph nodes or a single distant lymph node. the brain. bones.

What is the HerediGene study? ›

What is HerediGene®? HerediGene: Population Study aims to study the genes of 500,000 participants to better predict and prevent serious diseases.

What is the trustworthness of the study? ›

Trustworthiness or rigor of a study refers to the degree of confidence in data, interpretation, and methods used to ensure the quality of a study (Pilot & Beck, 2014).

How quickly do you deteriorate with lung cancer? ›

Studies have shown that lung cancer doubling time can vary, from 229 days to 647 days in one study, depending upon the type. 7 It's possible that some types of lung cancer progress within weeks to months, while others may take years to grow.

What is the progression of non-small cell lung cancer? ›

The earliest stage of NSCLC is stage 0 (also called carcinoma in situ, or CIS). Other stages range from I (1) through IV (4). As a rule, the lower the number, the less the cancer has spread. A higher number, such as stage IV, means cancer has spread more.

What is the prognosis for NSCLC metastasis? ›

Lung cancer patients are diagnosed as metastatic disease in 40–50% of the cases [3, 4], with a median survival of less than nine months [3, 5].

Is non-small cell lung cancer a fast growing cancer? ›

Non-small cell lung cancer is the most common type of lung cancer. It grows and spreads more slowly than small cell lung cancer.

References

Top Articles
Diablo IV Quarterly Update—October 2021
Diablo IV Quarterly Update—March 2022
Jackerman Mothers Warmth Part 3
Ati Capstone Orientation Video Quiz
Rochester Ny Missed Connections
Craigslist Pets Southern Md
3472542504
Where does insurance expense go in accounting?
Think Up Elar Level 5 Answer Key Pdf
Echo & the Bunnymen - Lips Like Sugar Lyrics
4156303136
Puretalkusa.com/Amac
G Switch Unblocked Tyrone
Kaitlyn Katsaros Forum
Morristown Daily Record Obituary
Puretalkusa.com/Amac
Betaalbaar naar The Big Apple: 9 x tips voor New York City
A Man Called Otto Showtimes Near Cinemark University Mall
Cb2 South Coast Plaza
Marilyn Seipt Obituary
Mikayla Campinos: Unveiling The Truth Behind The Leaked Content
Masterbuilt Gravity Fan Not Working
Tinyzonehd
Wolfwalkers 123Movies
How rich were the McCallisters in 'Home Alone'? Family's income unveiled
Best Restaurants Ventnor
100 Million Naira In Dollars
The Rise of "t33n leaks": Understanding the Impact and Implications - The Digital Weekly
Acuity Eye Group - La Quinta Photos
Cbs Trade Value Chart Week 10
Flaky Fish Meat Rdr2
Pnc Bank Routing Number Cincinnati
Capital Hall 6 Base Layout
Save on Games, Flamingo, Toys Games & Novelties
The Ride | Rotten Tomatoes
Tyler Sis 360 Boonville Mo
Why Gas Prices Are So High (Published 2022)
Dr Adj Redist Cadv Prin Amex Charge
Page 5662 – Christianity Today
Nancy Pazelt Obituary
Encompass.myisolved
Pokemon Reborn Gyms
Acts 16 Nkjv
Sdn Fertitta 2024
Fool's Paradise Showtimes Near Roxy Stadium 14
Sound Of Freedom Showtimes Near Amc Mountainside 10
Mynord
How To Get To Ultra Space Pixelmon
Mit diesen geheimen Codes verständigen sich Crew-Mitglieder
Freightliner Cascadia Clutch Replacement Cost
2487872771
Les BABAS EXOTIQUES façon Amaury Guichon
Latest Posts
Article information

Author: Ms. Lucile Johns

Last Updated:

Views: 5467

Rating: 4 / 5 (41 voted)

Reviews: 88% of readers found this page helpful

Author information

Name: Ms. Lucile Johns

Birthday: 1999-11-16

Address: Suite 237 56046 Walsh Coves, West Enid, VT 46557

Phone: +59115435987187

Job: Education Supervisor

Hobby: Genealogy, Stone skipping, Skydiving, Nordic skating, Couponing, Coloring, Gardening

Introduction: My name is Ms. Lucile Johns, I am a successful, friendly, friendly, homely, adventurous, handsome, delightful person who loves writing and wants to share my knowledge and understanding with you.